StocksFin Logo
Takeda Pharmaceutical Company Limited country of incorporation
|
|
Mr. Christophe Weber
|
47,347 employees
NYSE | Healthcare | Drug Manufacturers—Specialty & Generic
Boston Scientific Corporation country of incorporation
|
|
Mr. Michael Mahoney
|
41,000 employees
NYSE | Healthcare | Medical Devices
Q223 reported Sep 30, 2022 Reporting Period
$1T 18.6% vs. Q222 Revenues Q223
69.53% 3.2% vs. Q222 Gross Profit Margin
6.16% 13.2% vs. Q222 Net Profit Margin
180.38B -22.6% vs. Q222 Free Cash Flow Q223
$10 0% vs. Q222 EPS Q223
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q223
0.25%
Q322
0.03%
Q322 reported Nov 3, 2022 Reporting Period
$3.17B 8.1% vs. Q321 Revenues Q322
69.12% 0.4% vs. Q321 Gross Profit Margin
5.49% -61.6% vs. Q321 Net Profit Margin
320M -31.2% vs. Q321 Free Cash Flow Q322
$0.12 -57.1% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q223
0.25%
Q322
0.03%
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
0.68
0.62
Current Ratio
1.15
1.45
Cash Ratio
0.33
0.1
Price to Book
0.66
3.14
Price to Sales
4.42
17.49
Price to Earnings
17.95
79.66